Vertex Pharmaceuticals reported over $100 million in revenue from CASGEVY infusions during 2025, reflecting more than 60 patient treatments and underscoring strong commercial traction in its gene therapy franchise. The company also noted that JOURNAVX prescriptions exceeded 500,000 during the year, further demonstrating robust uptake of its cystic fibrosis portfolio across core markets.

Ahead of the J.P. Morgan Healthcare Conference, Vertex raised its patient population estimate for cystic fibrosis to approximately 112,000 globally, including about 97,000 in core markets. This adjustment reflects evolving epidemiological data and supports expanded commercial potential for its CF modulators.

Vertex expects to complete its rolling biologics license application for povetacicept in IgA nephropathy during the first half of 2026, leveraging a priority review voucher to shorten the FDA review period from ten months to six months. Concurrently, the company plans to conclude enrollment in two Phase 3 studies of suzetrigine for diabetic peripheral neuropathy by the end of 2026, positioning both programs for potential accelerated regulatory decisions.

Building on its CF success, Vertex is advancing an emerging renal franchise and several mid- and late-stage clinical candidates. Key focuses include potential near-term launches in kidney disease and progressive work on programs targeting sickle cell disease and pain, reflecting a strategic shift toward multiple high-value therapeutic areas beyond its core franchise.